{
    "thread": {
        "uuid": "28429b5b73fdbfb3cfe85a72e0261fa433867a00",
        "url": "https://tw.tradingview.com/news/reuters.com,2025:newsml_L4T3R12CA:0",
        "site_full": "tw.tradingview.com",
        "site": "tradingview.com",
        "site_section": "https://tw.tradingview.com/news",
        "site_categories": [],
        "section_title": "財經新聞與頭條新聞 — 市場分析 — TradingView",
        "site_title": null,
        "title": "瑞思邁季度利潤略超預期，擺脫關稅擔憂",
        "title_full": "瑞思邁季度利潤略超預期，擺脫關稅擔憂",
        "published": "2025-04-24T01:17:00.000+03:00",
        "replies_count": 0,
        "participants_count": 0,
        "site_type": "news",
        "country": "TW",
        "main_image": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
        "performance_score": 0,
        "domain_rank": 1181,
        "domain_rank_updated": "2025-04-22T00:00:00.000+03:00",
        "licensing_agency": [],
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "28429b5b73fdbfb3cfe85a72e0261fa433867a00",
    "url": "https://tw.tradingview.com/news/reuters.com,2025:newsml_L4T3R12CA:0",
    "ord_in_thread": 0,
    "author": null,
    "published": "2025-04-24T01:17:00.000+03:00",
    "title": "瑞思邁季度利潤略超預期，擺脫關稅擔憂",
    "text": "瑞思邁季度利潤略超預期，擺脫關稅擔憂\nRefinitiv\n瑞思邁 RMD周三公布的第三季度利潤超出華爾街預期，主要原因是市場對其用於控制常見睡眠障礙的睡眠呼吸暫停設備的需求。\n該公司生產連續氣道正壓(CPAP) 機，通過在睡眠中保持呼吸道通暢來控制常見的睡眠障礙，從而顯著改善睡眠質量。\n這家總部位於聖迭戈的公司股價在盤後交易中上漲了 2.6%，達到 220 美元。\n投資者也一直在密切關注醫療設備製造商計劃如何應對關稅，以及它們是否能從外匯匯率變動中獲益。\n瑞思邁表示，該公司已做好 \"充分準備\"，並已獲得豁免，預計美國關稅的出台不會對其財務業績產生重大影響。\n公司首席執行官米克-法雷爾（Mick Farrell）在財報發布後的電話會議上表示，公司即將在加利福尼亞州卡拉巴薩斯開設最新的生產基地，這將使公司目前在美國的生產規模擴大一倍。\n受睡眠設備和面罩需求增加的 影響，該公司的季度收入增長了8%，達到 12.9 億美元，符合預期。\n一些分析師曾預計，禮來公司 LLY的減肥藥Zepbound（屬於GLP-1類藥物）在美國獲批用於治療睡眠呼吸暫停，會減少對該公司設備的需求。\n瑞思邁已擺脫了這些擔憂，並表示預計追蹤睡眠健康和 GLP-1 療法的消費類可穿戴設備將鼓勵更多患者使用其設備。\n根據倫敦證券交易所集團（LSEG）匯編的數據，該公司在截至3月31日的季度中公布的調整後利潤為每股2.37美元 ，而預期為每股2.36美元 。",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "chinese",
    "sentiment": "positive",
    "categories": [
        "Economy, Business and Finance",
        "Health"
    ],
    "topics": [
        "Economy, Business and Finance->financial service",
        "Economy, Business and Finance->products and services",
        "Economy, Business and Finance->business reporting and performance",
        "Health->health care approach",
        "Health->medical condition",
        "Health->health treatment and procedure"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
        "persons": [],
        "locations": [],
        "organizations": []
    },
    "syndication": {
        "syndicated": null,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "trust": {
        "categories": [],
        "bias": null,
        "source": {
            "type": null,
            "city": null,
            "state": null,
            "country": null,
            "domain_type": null,
            "agency": null,
            "organization_name": null
        }
    },
    "rating": null,
    "crawled": "2025-04-24T02:13:06.327+03:00",
    "updated": "2025-04-24T02:13:06.327+03:00"
}